助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   前列腺癌内分泌治疗 的翻译结果: 查询用时:0.01秒
图标索引 在分类学科中查询
所有学科
泌尿科学
肿瘤学
更多类别查询

图标索引 历史查询
 

前列腺癌内分泌治疗
相关语句
  “前列腺癌内分泌治疗”译为未确定词的双语例句
     Evaluation of ~(153)Sm-EDTMP Therapy for Metastasis Prostate Cancer and Pain due to Bony Metastases after Hormone Therapy
     ~(153)Sm-EDTMP治疗前列腺癌内分泌治疗后骨转移骨痛的效果评价
短句来源
     Continuous androgen suppression (CAS) is currently the gold standard hormone therapy for advanced prostate cancer.
     背景目前晚期前列腺癌内分泌治疗的金标准是持续性雄激素抑制(Continuous androgen suppression, CAS)。
短句来源
     ObjectiveUsing magnetic resonance spectroscopy (MRS) to investigate the metabolic changes of prostate cancer after endocrine therapy.
     目的 用MRS定量评价前列腺癌内分泌治疗后的代谢变化 ,观察癌组织与非癌区外周带的代谢差别。
短句来源
     The Study of Monitoring Serum Testosterone to Guiding Endocrine Therapy of Prostate Cancer
     血清睾酮监测在前列腺癌内分泌治疗中的应用研究
短句来源
     Change of serum PSA and f-PSA contents in advanced prostate cancer patients treated with hormonal therapy
     晚期前列腺癌内分泌治疗后血清PSA、f-PSA含量的变化
短句来源
更多       
  相似匹配句对
     Hormonal therapy for metastatic prostate cancer
     转移性前列腺癌内分泌治疗
短句来源
     Some Issue on Endocrine Therapy in Prostate Cancer
     前列腺癌内分泌治疗中的几个问题
短句来源
     Up-to-date Study of Intermittent Endocrine Therapy for Prostate Cancer
     前列腺癌间断内分泌治疗研究现状
短句来源
     Effects of endocrine therapy on the primary lesions in patients with prostate cancer as evaluated by magnetic resonance imaging
     前列腺癌内分泌治疗疗效的MRI评价
短句来源
     Radiotherapy of Prostate Cancer
     前列腺癌的放射治疗
短句来源
查询“前列腺癌内分泌治疗”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
没有找到相关例句


Objective In order to improve the effect of hormone treatment for prostate cancer, a total of 17 such patients were treated with Enantone(chemical castration) from July 1990 to July 1992. Methods In the control group, 16 evaluable patients who were followed for 3 to 5 years, PSA was determined with ELISA. Commercial kit was used for determination of T, LH and FSH. Prostate lesion and metastasis and patient's status was eximination in the follow up. Results Enantone was ableto suppress plasma testosterone...

Objective In order to improve the effect of hormone treatment for prostate cancer, a total of 17 such patients were treated with Enantone(chemical castration) from July 1990 to July 1992. Methods In the control group, 16 evaluable patients who were followed for 3 to 5 years, PSA was determined with ELISA. Commercial kit was used for determination of T, LH and FSH. Prostate lesion and metastasis and patient's status was eximination in the follow up. Results Enantone was ableto suppress plasma testosterone concentration to the condition of castration during treatment ( P < 0.01 ). PSA and other markers also responded well. Significant improvement in performance status, micturition problems and general well being was reported. Conclusion The once a month administration of Enantone combined with flutamide is effective in the managemant of advanced prostate cancer with acceptable side effects.

目的为提高晚期前列腺癌内分泌治疗效果,1990年7月~1992年7月间对17例前列腺癌患者进行了抑那通(药物除睾)的临床观察。方法随访3~5年获得可评价资料16例病例,采用免疫酶联法测定PSA变化,放免法检测性激素水平,用I-PSS表调查排尿及生活质量,对前列腺及转移病灶、全身状况的变化进行对比观察。结果抑那通治疗后睾酮降至去势水平(P<0.01),前列腺特异抗原及其他肿瘤标记物提示反应性良好,症状及全身状况明显改善。结论每月注射一次抑那通,如果与抗男性素剂联合使用可获得更安全有效的治疗效果。

Objective To evaluate the effect of hormonal therapy on the MR imaging findings in patierts of prostate cancer. Methods MR imaging was studied in 36 patients 〔mean age ( 73.8± 8 2) years old〕 with prostatic cancer before and after hormonal treatment.MR imaging was performed on 1 5 T Scaner (Signa; General electric medical systems, Milwaukee, WI) and included axial plane T1 weighted images (TR/TE, 500/15) and axial/coronal plane fast spin echo T2 weighted images (TR/TE, 4 000/102) with a pelvic...

Objective To evaluate the effect of hormonal therapy on the MR imaging findings in patierts of prostate cancer. Methods MR imaging was studied in 36 patients 〔mean age ( 73.8± 8 2) years old〕 with prostatic cancer before and after hormonal treatment.MR imaging was performed on 1 5 T Scaner (Signa; General electric medical systems, Milwaukee, WI) and included axial plane T1 weighted images (TR/TE, 500/15) and axial/coronal plane fast spin echo T2 weighted images (TR/TE, 4 000/102) with a pelvic surface coil. Imaging evaluation included assessment of the gland size, signal intensity, tumor depiction, extracapsular extension and seminal vesicles invasion. Results All prostatic cancers in this study were diagnosed by biopsy. Overall accuracy of MR imaging diagnosis on prostatic cancers in this study was 91.7% (33 of 36 patients). After hormonal therapy, a mean decrease of (33 5±19 6)% ( P <0 01)in the volume of the prostate gland was showed by MR imaging. Volume reduction in the transitional zone 〔mean, (29 3±22.0)%〕 was less than that in the peripheral zone 〔mean, (55 8±23 3)%〕 ( P <0 05). On T2 weighted images, the signal intensity of peripheral zone showed homogeneous decreased in all patients by different degree. There was positive correlation between changes in the prostate volume and prostate specific antigen levels after hormonal therapy ( r =0 67, P <0 05). Conclusions Hormonal therapy caused a decrease in size and signal intensity of the prostate gland and seminal vesicles as detected by MR imaging. Significant correlation between decreases in the prostate volume and prostate specific antigen levels was also observed in this study.

目的 观察前列腺癌患者内分泌治疗前后前列腺的 MRI表现。 方法 分析 3 6例前列腺癌患者内分泌治疗前后前列腺体积的变化和信号的变化。 结果  3 6例经内分泌治疗后其前列腺体积平均缩小 ( 3 3 .5± 1 9.6) % ( P<0 .0 1 ) ,其中周围带体积缩小程度〔( 55.8± 2 3 .3 ) %〕大于移行带缩小程度〔( 2 9.3± 2 2 .0 ) %〕( P<0 .0 5) ;同时 ,在 T2加权像上前列腺周围带及移行带信号均显示不同程度的弥漫性减低 ;前列腺体积缩小与血清前列腺特异抗原 ( PSA)水平下降之间有显著性相关( r=0 .67,P<0 .0 5)。 结论 前列腺癌内分泌治疗后 MRI的表现为前列腺和精囊的体积缩小 ,信号减低。

Purpose :To evaluate the efficacies of orchiectomy plus flutamide and pure orchiectomy in the treatment of metastatic prostatic cancer.Materials and Methods:From 1983 to 1998,there were 65 patients with metastatic prostatic cancer treated at our department.55 examples were to be evaluated.In these patients,30 examples treated with orchiectomy plus flutamide were designed as group A,and 25 examples with pure orchiectomy,designed as group B.The main ...

Purpose :To evaluate the efficacies of orchiectomy plus flutamide and pure orchiectomy in the treatment of metastatic prostatic cancer.Materials and Methods:From 1983 to 1998,there were 65 patients with metastatic prostatic cancer treated at our department.55 examples were to be evaluated.In these patients,30 examples treated with orchiectomy plus flutamide were designed as group A,and 25 examples with pure orchiectomy,designed as group B.The main efficacy criteria including objective response to treatment,interval to progression,and two-year survival were analyzed.Individual response criteria including pain of metastatic origin,levels of AKP and PSA,and range of bone involvement were also analyzed.The differences of efficacy between group A and group B were evaluated.Results:If regression of disease was considered as objective response to treatment,the percentage of response was 43% in group A and 25% in group B ([WT5”BX]P[WT5”BZ]<0.001).If regression and stability of the disease were considered as objective response to treatment,the percentage of response was 77% in group A and 65% in group B([WT5”BX]P[WT5”BZ]<0.005).The mean interval to subjective progression was 16.3±5.5 months in group A and 15.8±5.8 months in group B([WT5”BX]P[WT5”BZ]>0.05).The mean interval to objective progression was 18.2±5.3 months in group A and 17.6±5.7 months in group B([WT5”BX]P[WT5”BZ]>0.05).The two-year survival was 36% in group A and 33% in group B([WT5”BX]P[WT5”BZ]>0.05).Significant differences in favor of the group A were found in analyzing the individual response criteria except performance status.Conclusions:Castration remains the gold standard of endocrine treatment.The combination of orchiectomy and flutamide has a more beneficial effect on pain of metastatic origin,levels of AKP and PSA,objective response to treatment,and range of bone involvement than pure orchiectomy.But,it has no additional value if time to progression and overall survival are considered.

目的 :评估睾丸切除联合缓退瘤与单纯睾丸切除治疗进展性前列腺癌的疗效。方法 :6 5例进展性前列腺癌病人中筛选了 5 5例进行评估。其中睾丸切除联合缓退瘤治疗的 30例 ,为A组 ;单纯睾丸切除治疗的 2 5例 ,为B组。所分析的主要疗效指标为客观治疗反应、进展间隔时间和两年生存率。对单项疗效评估指标包括全身情况、扩散性疼痛、AKP和PAS水平以及骨转移范围也进行了分析。评估A组和B组两组疗效的差异。结果 :如果以病变消退为治疗反应 ,A组的反应率为 43%而B组为 2 5 % (P <0 .0 0 1) ;若以病变消退和稳定为治疗反应 ,则A组的反应率为 77%而B组为 6 5 % (P <0 .0 0 5 )。平均主观进展时间 :A组为 16 .3± 5 .5个月而B组为 15 .8± 5 .8个月 (P >0 .0 5 ) ;平均客观进展时间 :A组为 18.2± 5 .3个月而B组为 17.6± 5 .7个月 (P >0 .0 5 )。两年生存率 :A组 36 %而B组 33 % (P >0 .0 5 )。在分析单项疗效评估指标时发现 :除全身情况外 ,A组较B组有显著性差异。结论 :睾丸去势仍然是#...

目的 :评估睾丸切除联合缓退瘤与单纯睾丸切除治疗进展性前列腺癌的疗效。方法 :6 5例进展性前列腺癌病人中筛选了 5 5例进行评估。其中睾丸切除联合缓退瘤治疗的 30例 ,为A组 ;单纯睾丸切除治疗的 2 5例 ,为B组。所分析的主要疗效指标为客观治疗反应、进展间隔时间和两年生存率。对单项疗效评估指标包括全身情况、扩散性疼痛、AKP和PAS水平以及骨转移范围也进行了分析。评估A组和B组两组疗效的差异。结果 :如果以病变消退为治疗反应 ,A组的反应率为 43%而B组为 2 5 % (P <0 .0 0 1) ;若以病变消退和稳定为治疗反应 ,则A组的反应率为 77%而B组为 6 5 % (P <0 .0 0 5 )。平均主观进展时间 :A组为 16 .3± 5 .5个月而B组为 15 .8± 5 .8个月 (P >0 .0 5 ) ;平均客观进展时间 :A组为 18.2± 5 .3个月而B组为 17.6± 5 .7个月 (P >0 .0 5 )。两年生存率 :A组 36 %而B组 33 % (P >0 .0 5 )。在分析单项疗效评估指标时发现 :除全身情况外 ,A组较B组有显著性差异。结论 :睾丸去势仍然是前列腺癌内分泌治疗的金标准。睾丸切除联合缓退瘤治疗在病变的消退和稳定、扩散性疼痛的缓解、AKP和PSA的水平的恢复和骨转移范围缩小方面较单纯睾丸切除有较好的效果。但是 ,就进展时间和生存率而言并无更大的价值。

 
<< 更多相关文摘    
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关前列腺癌内分泌治疗的内容
在知识搜索中查有关前列腺癌内分泌治疗的内容
在数字搜索中查有关前列腺癌内分泌治疗的内容
在概念知识元中查有关前列腺癌内分泌治疗的内容
在学术趋势中查有关前列腺癌内分泌治疗的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社